| Followers | 3 |
| Posts | 1873 |
| Boards Moderated | 0 |
| Alias Born | 02/07/2016 |
Saturday, May 17, 2025 9:40:28 AM
Yet another post from you with personal attacks and not a shred of reason, evidence, or examples to support your position.
I have provided examples (large and small companies including 5 in biotech), commonly known and accepted reasons and recent news related to this topic all showing the positive effects of insider purchases. With the following concrete evidence, I will rest my case and put you on ignore. I think with your last post, you lost the reapect of most readers on this board.
Multiple academic studies show positive correlation between insider purchases and stock returns (see link below):
"At the level of individual firms, Lakonishok and Lee concluded that insider activity can predict stock returns.They found that stocks with extensive insider purchases outperformed those with extensive sales. However, they stated that insider purchases are more informative than insider sales.
"Research showed that long-term positive (negative) excess returns existed afterinsider purchase (sale) transactions. It also showed that multiple trades by different insiders in the same direction led to higher excess returns."
https://www.2iqresearch.com/blog/profiting-from-insider-transactions-a-review-of-the-academic-research
I have provided examples (large and small companies including 5 in biotech), commonly known and accepted reasons and recent news related to this topic all showing the positive effects of insider purchases. With the following concrete evidence, I will rest my case and put you on ignore. I think with your last post, you lost the reapect of most readers on this board.
Multiple academic studies show positive correlation between insider purchases and stock returns (see link below):
"At the level of individual firms, Lakonishok and Lee concluded that insider activity can predict stock returns.They found that stocks with extensive insider purchases outperformed those with extensive sales. However, they stated that insider purchases are more informative than insider sales.
"Research showed that long-term positive (negative) excess returns existed afterinsider purchase (sale) transactions. It also showed that multiple trades by different insiders in the same direction led to higher excess returns."
https://www.2iqresearch.com/blog/profiting-from-insider-transactions-a-review-of-the-academic-research
Recent HALO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:28:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 10:35:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/23/2026 08:16:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/23/2026 08:13:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/23/2026 08:11:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:32:00 PM
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer • PR Newswire (US) • 03/12/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:05:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:18:04 PM
- U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma • PR Newswire (US) • 03/06/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:56:16 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/25/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:16:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:51:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:04:55 PM
- HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 02/17/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 02:21:33 AM
